QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
NASDAQ:AXNX

Axonics (AXNX) Stock Price, News & Analysis

$68.13
+0.25 (+0.37%)
(As of 02/22/2024 ET)
Today's Range
$67.86
$68.15
50-Day Range
$56.67
$69.36
52-Week Range
$47.59
$69.68
Volume
761,667 shs
Average Volume
1.69 million shs
Market Capitalization
$3.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.09

Axonics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.42 Rating Score
Upside/​Downside
4.3% Upside
$71.09 Price Target
Short Interest
Bearish
5.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.38
Upright™ Environmental Score
News Sentiment
1.07mentions of Axonics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$6.07 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.20) to $0.30 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.45 out of 5 stars

Medical Sector

297th out of 934 stocks

Surgical & Medical Instruments Industry

40th out of 91 stocks


AXNX stock logo

About Axonics Stock (NASDAQ:AXNX)

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

AXNX Stock Price History

AXNX Stock News Headlines

Analysts Set Axonics, Inc. (NASDAQ:AXNX) Price Target at $71.09
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
Axonics just downgraded at Morgan Stanley, here's why
Axonics just downgraded at Truist, here's why
Axonics just downgraded at CL King, here's why
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
Axonics just downgraded at Leerink, here's why
Analyst Scoreboard: 5 Ratings For Axonics
Axonics just downgraded at RBC Capital, here's why
Why Is Axonics (AXNX) Stock Up 20% Today?
Peeling Back The Layers: Exploring Axonics Through Analyst Insights
When Will Axonics, Inc. (NASDAQ:AXNX) Become Profitable?
Axonics to Participate in November Investor Conferences
Axonics: Q3 Earnings Snapshot
See More Headlines
Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/30/2023
Today
2/22/2024
Next Earnings (Estimated)
3/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:AXNX
Employees
610
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$71.09
High Stock Price Target
$75.00
Low Stock Price Target
$63.00
Potential Upside/Downside
+4.5%
Consensus Rating
Hold
Rating Score (0-4)
2.42
Research Coverage
12 Analysts

Profitability

Net Income
$-59,700,000.00
Pretax Margin
-4.10%

Debt

Sales & Book Value

Annual Sales
$342.56 million
Book Value
$11.51 per share

Miscellaneous

Free Float
49,725,000
Market Cap
$3.45 billion
Optionable
Optionable
Beta
0.63
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives















AXNX Stock Analysis - Frequently Asked Questions

Should I buy or sell Axonics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AXNX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AXNX, but not buy additional shares or sell existing shares.
View AXNX analyst ratings
or view top-rated stocks.

What is Axonics' stock price target for 2024?

12 equities research analysts have issued 1-year price objectives for Axonics' shares. Their AXNX share price targets range from $63.00 to $75.00. On average, they predict the company's share price to reach $71.09 in the next twelve months. This suggests a possible upside of 4.3% from the stock's current price.
View analysts price targets for AXNX
or view top-rated stocks among Wall Street analysts.

How have AXNX shares performed in 2024?

Axonics' stock was trading at $62.23 at the beginning of 2024. Since then, AXNX shares have increased by 9.5% and is now trading at $68.13.
View the best growth stocks for 2024 here
.

Are investors shorting Axonics?

Axonics saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 2,680,000 shares, an increase of 131.0% from the January 15th total of 1,160,000 shares. Based on an average daily trading volume, of 1,110,000 shares, the short-interest ratio is currently 2.4 days.
View Axonics' Short Interest
.

When is Axonics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our AXNX earnings forecast
.

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) posted its earnings results on Monday, October, 30th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.13. The company earned $93.10 million during the quarter, compared to analysts' expectations of $89.60 million. Axonics had a negative trailing twelve-month return on equity of 2.04% and a negative net margin of 3.50%. Axonics's revenue was up 32.3% compared to the same quarter last year. During the same period last year, the business posted ($0.34) EPS.

What guidance has Axonics issued on next quarter's earnings?

Axonics issued an update on its fourth quarter 2023 earnings guidance on Monday, January, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $109.3 million-$109.7 million, compared to the consensus revenue estimate of $105.5 million.

What is Raymond W. Cohen's approval rating as Axonics' CEO?

20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include RTX (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

(AXNX) raised $100 million in an IPO on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Who are Axonics' major shareholders?

Axonics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.38%), Bellevue Group AG (3.62%), Mackenzie Financial Corp (2.47%), Artisan Partners Limited Partnership (2.41%), Dimensional Fund Advisors LP (1.82%) and Wasatch Advisors LP (1.39%). Insiders that own company stock include Alfred J Ford Jr, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Kari Leigh Keese, Raymond W Cohen, Raymond W Cohen and Rinda Sama.
View institutional ownership trends
.

How do I buy shares of Axonics?

Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXNX) was last updated on 2/22/2024 by MarketBeat.com Staff